Research programme: single- and multi-targeted CAR-T cell therapeutics - Abound Bio/Vor BioPharma
Latest Information Update: 23 Jun 2022
At a glance
- Originator Abound Bio; Vor Biopharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Acute myeloid leukaemia; Haematological malignancies
Most Recent Events
- 21 Jun 2022 Abound Bio has been acquired by Galapagos NV
- 10 Jun 2021 Vor Biopharma and Abound Bio agree to co-develop single- and multi-targeted CAR-T cell therapeutics for Acute myeloid leukaemia and Haematological malignancies
- 10 Jun 2021 Early research in Acute myeloid leukaemia in USA (Parenteral)